Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
J

One of the Toughest Parts of Treatment: Managing "Scanxiety"

By Dana-Farber Cancer Institute FEATURING Jess Mosey
By Dana-Farber Cancer Institute FEATURING Jess Mosey
1 view
April 3, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
2023-2024 EMBRACE MBC Virtual Forum Series
11:40
Dana-Farber Cancer Institute

One of the Toughest Parts of Treatment: Managing "Scanxiety&quo…

Feat. J. Mosey
18:07
Dana-Farber Cancer Institute

Concepts of Treatment, Progression, and Staging in mBC

Feat. S. Sammons
34:39
Dana-Farber Cancer Institute

Sexual Health and Sexual Recovery for Adults Living With mBC

Feat. S. Bober
15:26
Dana-Farber Cancer Institute

Antibody Drug Conjugates Highlights - mBC Series

Feat. H. Burstein
04:04
Dana-Farber Cancer Institute

Metastatic Disease Survivors - mBC Series

Feat. H. Burstein
10:25
Dana-Farber Cancer Institute

ER+ Disease Highlights - mBC Series

Feat. H. Burstein
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
16:03
Dana-Farber Cancer Institute

What’s New in Research for ER+ mBC

Feat. A. Giordano
18:08
Dana-Farber Cancer Institute

Current Treatment Options for Patients With HER2+ mBC

Feat. N. Lin
15:37
Dana-Farber Cancer Institute

HER2+ mBC: What’s Coming Up in Research?

Feat. A. Waks
19:50
Dana-Farber Cancer Institute

What's New in Treatment for TNBC

Feat. M. Tesch
24:29
Dana-Farber Cancer Institute

What's New in Research for mTNBC

Feat. P. Tarantino
11:10
Dana-Farber Cancer Institute

Antibody Drug Conjugates in Breast Cancer

Feat. S. Tolaney
28:21
Dana-Farber Cancer Institute

Recent Advances in mBC and Update on the EMBRACE Program

Feat. N. Lin